IND: (+91) 949418 5556
sales@envisioninteligence.com
- Home
- Industry Reports
- Global Biomarkers Market, Size, Share, Trends, Forecast (2020 – 2026)
Introduction:
Biomarkers, also known as molecular markers or signature molecules, can be used to check that how body responds to any illness or disease being treated. They are used to examine the functions of the organs and other health conditions, in simple words. They are also used in imaging technology to provide precise imaging of tumours and other problems in oncology. They are also used in early phase clinical trials to assess drug results and effects.
Global Biomarkers Market Size & Growth:
The global biomarkers market was valued at $XX Billion in 2018 and is estimated to reach $XX Billion by 2026, growing at a CAGR of around X.XX% during the forecast period. Growth in the global biomarker industry is driven primarily by factors such as growing biomarker diagnostic applications, rising R&D funding for pharmaceutical and biotech companies, greater prevalence of CROs and low cost clinical trials in developing countries, high cancer prevalence and new research initiatives. On the other hand, the major factors hampering the growth of this market are high capital investment and a low cost-benefit ratio, poorly suited regulatory and reimbursement processes, and technical issues related to sample collection and storage. Moreover, paradigm shift towards personalized medicine for cancer treatments, development of OMICS technology and rising interdisciplinary systems biology approach is expected to drive the market for biomarkers.
Global Biomarkers Market Segmentation:
The global biomarkers market is segregated on the basis of product, type, disease indication, application, and geography. By product, the biomarkers market is segmented into consumables, services, and software. The consumables segment accounted for the largest share of the global biomarkers market, primarily due to the increasing use of reagent kits and assays for biomarker testing and the higher frequency of purchase of consumables.
Based on type segment, the biomarkers market is bifurcated into safety, efficacy, and validation biomarkers. The efficacy biomarkers segment is further segmented into predictive, surrogate, pharmacodynamics, and prognostic biomarkers.
By disease indication, this report is segmented into cancer, cardiovascular disorders, neurological disorders, immunological disorders, and other disease indications. Cancer forms the largest segment primarily due to the rising prevalence of cancer globally and the growing application of biomarkers in cancer diagnostics.
Biomarkers are mainly used in diagnostics, drug discovery & development, personalized medicine, disease risk assessment, and other applications. Moreover, increasing use of biomarkers for the diagnosis of multiple diseases, including cancer, cardiovascular disorders, and neurological disorders is the major factor that drives the growth of diagnostic segment of the biomarker market.
Based on region, has been segmented into North America, South America, Europe, Asia-Pacific, and the Middle East & Africa. North America held the largest market share for biomarkers attributed to increasing developments in diagnostic applications of biomarkers, spurring R&D funding for biomarker research, and high prevalence of cancer. Europe accounts for the second-largest share in the global biomarkers market owing to the presence of favorable government initiatives and laws, large target population base, rising prevalence of lifestyle-associated conditions, and increasing adoption rate of biomarker dependent diagnostic tests.
Global Biomarkers Market Trends:
- In March 2020, F. Hoffmann-La Roche Ltd declared the approval by the US Food and Drug Administration (FDA) for its CINtec PLUS Cytology as the first biomarker-based triage test for women whose primary cervical cancer screening results are positive for the human papillomavirus (HPV) using the cobas 4800 HPV Test
- In November 2019, Merck and Personalis, a cancer genomics company, come into into a partnership to identify and develop novel clinical biomarkers for cancer therapies. Under the terms of the partnership, Merck strategies to use Personalis’ newest cancer immunogenomics platform ImmunoID NeXT for clinical biomarker identification and development
Global Biomarkers Market Research Report Include:
- An executive summary condensing the whole report such that essential authority can rapidly twist up doubtlessly acquainted with brief overview and conclusion.
- To have complete market analysis through industry value chain analysis, porter’s five, PESTLE, SWOT analysis, and Y-o-Y analysis.
- Regional and global diversity is analyzed with the major countries and the unions. Scrutinizing the revenue generation on Year-On-Year
- Identifying DROC in the current market and their impact in altering the market dynamics.
- Competitive landscape analysis to identify the merger and acquisition which will have a comparative financial analysis with major competitors.
- Expertise investment opportunities by analyst to the individual and organization to have better foothold in the market.
- Identify the latest developments, market shares and strategies that are employed by the major market players, such as
- Qiagen N.V.
- Perkinelmer, Inc.
- Bio-Rad Laboratories, Inc.
- Hoffmann-La Roche Ltd
- MilliporeSigma
Along with these companies, there were many other companies considered/ cited in the report while analyzing the biomarkers market. These companies hold substantial share-owning to the nature of the industry whereas rest of the market shares are marginal chunks to regional and local level manufacturers. other players have considerable presence owing to its robust brand image, geographical reach, and strong customer base.
CHAPTER 1 INTRODUCTION
1.1. Market Definition
1.2. Executive Summary
1.3. The Scope of the Study
CHAPTER 2 RESEARCH METHODOLOGY
2.1. Secondary Research
2.2. Primary Research
2.3. Analytic Tools and Model
2.4. Economic Indicator
2.4.1. Base Year, Base Currency, Forecasting Period
2.5. Expert Validation
2.6. Study Timeline
CHAPTER 3 MARKET ANALYSIS
3.1. Industry Value Chain Analysis
3.2. Porter’s Five Force Analysis
3.2.1. Bargaining Power of Buyers
3.2.2. Bargaining Power of Suppliers
3.2.3. Threats of Substitutes
3.2.4. Threats of New Entrants
3.2.5. Degree of Competition
3.3. PESTLE Analysis
3.3.1. Political
3.3.2. Economical
3.3.3. Social
3.3.4. Technological
3.3.5. Legal
3.3.6. Environmental
3.4. SWOT Analysis
3.4.1. Strengths
3.4.2. Weakness
3.4.3. Opportunities
3.4.4. Threats
3.5. Y-O-Y Analysis
CHAPTER 4 MARKET DYNAMICS
4.1. Market Drivers
4.1.1. Growing diagnostic applications of biomarkers
4.1.2. Increasing prevalence of cancer
4.1.3. Rising number of CROs and low cost of clinical trials in developing countries
4.1.4. Increasing R&D funding for pharma and biotech companies
4.2. Market Restraints & Challenges
4.2.1. High capital investments and low cost-benefit ratio
4.2.2. Technical issues related to sample collection and storage
4.3. Market Opportunities
4.3.1. Development of OMICS technology
4.3.2. Rising interdisciplinary systems biology approach
4.3.3. Paradigm shift towards personalized medicine for cancer treatments
CHAPTER 5 GLOBAL BIOMARKERS MARKET – BY PRODUCT
5.1. Introduction
5.2. Consumables
5.3. Services
5.4. Software
CHAPTER 6 GLOBAL BIOMARKERS MARKET – BY TYPE
6.1. Introduction
6.2. Safety Biomarkers
6.3. Efficacy Biomarkers
6.4. Validation Biomarkers
CHAPTER 7 GLOBAL BIOMARKERS MARKET – BY DISEASE INDICATION
7.1. Introduction
7.2. Cancer
7.3. Cardiovascular Disorders
7.4. Neurological Disorders
7.5. Immunological Disorders
7.6. Others
CHAPTER 8 GLOBAL BIOMARKERS MARKET – BY APPLICATION
8.1. Introduction
8.2. Diagnostics
8.3. Drug Discovery and Development
8.4. Personalized Medicine
8.5. Disease Risk Assessment
8.6. Others
CHAPTER 9 GLOBAL BIOMARKERS MARKET – BY GEOGRAPHY
9.1. Introduction
9.2. North America
9.2.1. U.S.
9.2.2. Canada
9.2.3. Mexico
9.2.4. Costa Rica
9.3. South America
9.3.1. Brazil
9.3.2. Argentina
9.3.3. Chile
9.3.4. Columbia
9.3.5. Others
9.4. Europe
9.4.1. U.K.
9.4.2. Germany
9.4.3. France
9.4.4. Italy
9.4.5. Spain
9.4.6. Russia
9.4.7. Netherlands
9.4.8. Switzerland
9.4.9. Poland
9.4.10. Others
9.5. Asia Pacific
9.5.1. China
9.5.2. Japan
9.5.3. India
9.5.4. South Korea
9.5.5. Australia & New Zealand
9.5.6. Malaysia
9.5.7. Singapore
9.5.8. Others
9.6. Middle East & Africa
9.6.1. UAE
9.6.2. Saudi Arabia
9.6.3. Iran
9.6.4. Iraq
9.6.5. Qatar
9.6.6. South Africa
9.6.7. Algeria
9.6.8. Morocco
9.6.9. Nigeria
9.6.10. Egypt
9.6.11. Others
CHAPTER 10 GLOBAL BIOMARKERS MARKET – COMPANY PROFILES
10.1. Qiagen N.V.
10.2. Perkinelmer, Inc.
10.3. Bio-Rad Laboratories, Inc.
10.4. MilliporeSigma
10.5. Enzo Biochem, Inc.
10.6. F. Hoffmann-La Roche Ltd.
10.7. Meso Scale Diagnostics, LLC
10.8. Signosis
10.9. Thermo Fisher Scientific Inc.
10.10. Siemens Healthineers AG
10.11. Epigenomics AG
10.12. Agilent Technologies, Inc.
10.13. Johnson & Johnson Services, Inc.
10.14. EKF Diagnostics Holdings, Inc.
CHAPTER 11 GLOBAL BIOMARKERS MARKET – COMPETITIVE LANDSCAPE
11.1. Market Share Analysis
11.2. Strategies adopted by top companies
11.3. Mergers, Acquisitions, Collaborations & Agreements
CHAPTER 12 MARKET INSIGHTS
12.1. Industry Experts Insights
12.2. Analysts Opinions
12.3. Investment Opportunities
CHAPTER 13 APPENDIX
13.1. List of Tables
13.2. List of Figures
- Competitive Analysis in marketing and strategic management is an assessment of the strengths and weaknesses of current and potential competitors.
- Monitoring the external and internal factors which affect the market dynamics with the aid of PESTLE analysis.
- The Regional and Global Variety is taken care of in the report.
- Year on Year basis generation of revenue is studied.
- Porter's Five Forces analyze the intensity of competition in an industry and its profitability level.
- The overview and the sustainability of the market are analyzed through SWOT.
- DROC (Drivers, Restraints, Opportunities and Challenges) is recognized in the current market scenario and see how its effect on market dynamics.
- The segment-level analysis in terms of type and technology.
- The value chain analysis, value that's created and captured by a company is the profit margin.
- Value Created and Captured – Cost of Creating that Value = Margin
- An executive summary consists of the whole report and the outcome is been given in the report to have brief knowledge about the report.
- Basis on the depth of the study we approach using analytical tools
- Expertise investment opportunities are given after analyzing the market to give the organization and the individual to have perfect knowledge about the market.
Global Report
$2,700.00 – $8,100.00
- EUR: €2,482.76 - €7,448.28
- INR: ₹221,957.38 - ₹665,872.14
- AED: د.إ9,909.00 - د.إ29,727.00
- GBP: £2,182.84 - £6,548.52
Additional information
| Report Type | Extensive Report, Miniature report, Snapshot Report |
|---|---|
| Licence | Single User License, Team License, Corporate License |
Introduction:
Biomarkers, also known as molecular markers or signature molecules, can be used to check that how body responds to any illness or disease being treated. They are used to examine the functions of the organs and other health conditions, in simple words. They are also used in imaging technology to provide precise imaging of tumours and other problems in oncology. They are also used in early phase clinical trials to assess drug results and effects.
Global Biomarkers Market Size & Growth:
The global biomarkers market was valued at $XX Billion in 2018 and is estimated to reach $XX Billion by 2026, growing at a CAGR of around X.XX% during the forecast period. Growth in the global biomarker industry is driven primarily by factors such as growing biomarker diagnostic applications, rising R&D funding for pharmaceutical and biotech companies, greater prevalence of CROs and low cost clinical trials in developing countries, high cancer prevalence and new research initiatives. On the other hand, the major factors hampering the growth of this market are high capital investment and a low cost-benefit ratio, poorly suited regulatory and reimbursement processes, and technical issues related to sample collection and storage. Moreover, paradigm shift towards personalized medicine for cancer treatments, development of OMICS technology and rising interdisciplinary systems biology approach is expected to drive the market for biomarkers.
Global Biomarkers Market Segmentation:
The global biomarkers market is segregated on the basis of product, type, disease indication, application, and geography. By product, the biomarkers market is segmented into consumables, services, and software. The consumables segment accounted for the largest share of the global biomarkers market, primarily due to the increasing use of reagent kits and assays for biomarker testing and the higher frequency of purchase of consumables.
Based on type segment, the biomarkers market is bifurcated into safety, efficacy, and validation biomarkers. The efficacy biomarkers segment is further segmented into predictive, surrogate, pharmacodynamics, and prognostic biomarkers.
By disease indication, this report is segmented into cancer, cardiovascular disorders, neurological disorders, immunological disorders, and other disease indications. Cancer forms the largest segment primarily due to the rising prevalence of cancer globally and the growing application of biomarkers in cancer diagnostics.
Biomarkers are mainly used in diagnostics, drug discovery & development, personalized medicine, disease risk assessment, and other applications. Moreover, increasing use of biomarkers for the diagnosis of multiple diseases, including cancer, cardiovascular disorders, and neurological disorders is the major factor that drives the growth of diagnostic segment of the biomarker market.
Based on region, has been segmented into North America, South America, Europe, Asia-Pacific, and the Middle East & Africa. North America held the largest market share for biomarkers attributed to increasing developments in diagnostic applications of biomarkers, spurring R&D funding for biomarker research, and high prevalence of cancer. Europe accounts for the second-largest share in the global biomarkers market owing to the presence of favorable government initiatives and laws, large target population base, rising prevalence of lifestyle-associated conditions, and increasing adoption rate of biomarker dependent diagnostic tests.
Global Biomarkers Market Trends:
- In March 2020, F. Hoffmann-La Roche Ltd declared the approval by the US Food and Drug Administration (FDA) for its CINtec PLUS Cytology as the first biomarker-based triage test for women whose primary cervical cancer screening results are positive for the human papillomavirus (HPV) using the cobas 4800 HPV Test
- In November 2019, Merck and Personalis, a cancer genomics company, come into into a partnership to identify and develop novel clinical biomarkers for cancer therapies. Under the terms of the partnership, Merck strategies to use Personalis’ newest cancer immunogenomics platform ImmunoID NeXT for clinical biomarker identification and development
Global Biomarkers Market Research Report Include:
- An executive summary condensing the whole report such that essential authority can rapidly twist up doubtlessly acquainted with brief overview and conclusion.
- To have complete market analysis through industry value chain analysis, porter’s five, PESTLE, SWOT analysis, and Y-o-Y analysis.
- Regional and global diversity is analyzed with the major countries and the unions. Scrutinizing the revenue generation on Year-On-Year
- Identifying DROC in the current market and their impact in altering the market dynamics.
- Competitive landscape analysis to identify the merger and acquisition which will have a comparative financial analysis with major competitors.
- Expertise investment opportunities by analyst to the individual and organization to have better foothold in the market.
- Identify the latest developments, market shares and strategies that are employed by the major market players, such as
- Qiagen N.V.
- Perkinelmer, Inc.
- Bio-Rad Laboratories, Inc.
- Hoffmann-La Roche Ltd
- MilliporeSigma
Along with these companies, there were many other companies considered/ cited in the report while analyzing the biomarkers market. These companies hold substantial share-owning to the nature of the industry whereas rest of the market shares are marginal chunks to regional and local level manufacturers. other players have considerable presence owing to its robust brand image, geographical reach, and strong customer base.
CHAPTER 1 INTRODUCTION
1.1. Market Definition
1.2. Executive Summary
1.3. The Scope of the Study
CHAPTER 2 RESEARCH METHODOLOGY
2.1. Secondary Research
2.2. Primary Research
2.3. Analytic Tools and Model
2.4. Economic Indicator
2.4.1. Base Year, Base Currency, Forecasting Period
2.5. Expert Validation
2.6. Study Timeline
CHAPTER 3 MARKET ANALYSIS
3.1. Industry Value Chain Analysis
3.2. Porter’s Five Force Analysis
3.2.1. Bargaining Power of Buyers
3.2.2. Bargaining Power of Suppliers
3.2.3. Threats of Substitutes
3.2.4. Threats of New Entrants
3.2.5. Degree of Competition
3.3. PESTLE Analysis
3.3.1. Political
3.3.2. Economical
3.3.3. Social
3.3.4. Technological
3.3.5. Legal
3.3.6. Environmental
3.4. SWOT Analysis
3.4.1. Strengths
3.4.2. Weakness
3.4.3. Opportunities
3.4.4. Threats
3.5. Y-O-Y Analysis
CHAPTER 4 MARKET DYNAMICS
4.1. Market Drivers
4.1.1. Growing diagnostic applications of biomarkers
4.1.2. Increasing prevalence of cancer
4.1.3. Rising number of CROs and low cost of clinical trials in developing countries
4.1.4. Increasing R&D funding for pharma and biotech companies
4.2. Market Restraints & Challenges
4.2.1. High capital investments and low cost-benefit ratio
4.2.2. Technical issues related to sample collection and storage
4.3. Market Opportunities
4.3.1. Development of OMICS technology
4.3.2. Rising interdisciplinary systems biology approach
4.3.3. Paradigm shift towards personalized medicine for cancer treatments
CHAPTER 5 GLOBAL BIOMARKERS MARKET – BY PRODUCT
5.1. Introduction
5.2. Consumables
5.3. Services
5.4. Software
CHAPTER 6 GLOBAL BIOMARKERS MARKET – BY TYPE
6.1. Introduction
6.2. Safety Biomarkers
6.3. Efficacy Biomarkers
6.4. Validation Biomarkers
CHAPTER 7 GLOBAL BIOMARKERS MARKET – BY DISEASE INDICATION
7.1. Introduction
7.2. Cancer
7.3. Cardiovascular Disorders
7.4. Neurological Disorders
7.5. Immunological Disorders
7.6. Others
CHAPTER 8 GLOBAL BIOMARKERS MARKET – BY APPLICATION
8.1. Introduction
8.2. Diagnostics
8.3. Drug Discovery and Development
8.4. Personalized Medicine
8.5. Disease Risk Assessment
8.6. Others
CHAPTER 9 GLOBAL BIOMARKERS MARKET – BY GEOGRAPHY
9.1. Introduction
9.2. North America
9.2.1. U.S.
9.2.2. Canada
9.2.3. Mexico
9.2.4. Costa Rica
9.3. South America
9.3.1. Brazil
9.3.2. Argentina
9.3.3. Chile
9.3.4. Columbia
9.3.5. Others
9.4. Europe
9.4.1. U.K.
9.4.2. Germany
9.4.3. France
9.4.4. Italy
9.4.5. Spain
9.4.6. Russia
9.4.7. Netherlands
9.4.8. Switzerland
9.4.9. Poland
9.4.10. Others
9.5. Asia Pacific
9.5.1. China
9.5.2. Japan
9.5.3. India
9.5.4. South Korea
9.5.5. Australia & New Zealand
9.5.6. Malaysia
9.5.7. Singapore
9.5.8. Others
9.6. Middle East & Africa
9.6.1. UAE
9.6.2. Saudi Arabia
9.6.3. Iran
9.6.4. Iraq
9.6.5. Qatar
9.6.6. South Africa
9.6.7. Algeria
9.6.8. Morocco
9.6.9. Nigeria
9.6.10. Egypt
9.6.11. Others
CHAPTER 10 GLOBAL BIOMARKERS MARKET – COMPANY PROFILES
10.1. Qiagen N.V.
10.2. Perkinelmer, Inc.
10.3. Bio-Rad Laboratories, Inc.
10.4. MilliporeSigma
10.5. Enzo Biochem, Inc.
10.6. F. Hoffmann-La Roche Ltd.
10.7. Meso Scale Diagnostics, LLC
10.8. Signosis
10.9. Thermo Fisher Scientific Inc.
10.10. Siemens Healthineers AG
10.11. Epigenomics AG
10.12. Agilent Technologies, Inc.
10.13. Johnson & Johnson Services, Inc.
10.14. EKF Diagnostics Holdings, Inc.
CHAPTER 11 GLOBAL BIOMARKERS MARKET – COMPETITIVE LANDSCAPE
11.1. Market Share Analysis
11.2. Strategies adopted by top companies
11.3. Mergers, Acquisitions, Collaborations & Agreements
CHAPTER 12 MARKET INSIGHTS
12.1. Industry Experts Insights
12.2. Analysts Opinions
12.3. Investment Opportunities
CHAPTER 13 APPENDIX
13.1. List of Tables
13.2. List of Figures
- Competitive Analysis in marketing and strategic management is an assessment of the strengths and weaknesses of current and potential competitors.
- Monitoring the external and internal factors which affect the market dynamics with the aid of PESTLE analysis.
- The Regional and Global Variety is taken care of in the report.
- Year on Year basis generation of revenue is studied.
- Porter's Five Forces analyze the intensity of competition in an industry and its profitability level.
- The overview and the sustainability of the market are analyzed through SWOT.
- DROC (Drivers, Restraints, Opportunities and Challenges) is recognized in the current market scenario and see how its effect on market dynamics.
- The segment-level analysis in terms of type and technology.
- The value chain analysis, value that's created and captured by a company is the profit margin.
- Value Created and Captured – Cost of Creating that Value = Margin
- An executive summary consists of the whole report and the outcome is been given in the report to have brief knowledge about the report.
- Basis on the depth of the study we approach using analytical tools
- Expertise investment opportunities are given after analyzing the market to give the organization and the individual to have perfect knowledge about the market.
Our Clientele
Exclusive Benefits
Credibility and Transparency
We actively recruit consumers, business professionals, and hard-to-reach individuals as members of our research panels, and we build trusted, ongoing relationships with them. Thus we provide the complete list of primary and secondary data sources in the report to maintain the transparency and to assure the credibility.
Exhaustive Coverage
Detailed and extensive coverage in the geography.Survey consultation for brand tracking, concept testing, consumer behaviour, and more, we have you covered with market research services that scale to meet your needs.
Competitive Edge
Our reports cover most recent updates in the market till the date of the purchase. We identify, gather and timely deliver analysis on impact of unprecedented decisions of CXOs in COVID-19 catastrophe on many businesses, their clients and their clients' clients without additional cost.
Golden Opportunities
A comprehensive strategic sieve analysis of the market by our analysts and consultants, aided by AI tools helps us find the non-obvious, golden and emerging opportunities for you to evaluate.
Top-notch Reports Guaranteed
70% of our research is exclusive; no other research firm has the depth and breadth of our research.
Post Purchase Support
Post-purchase support is provided for all our reports, for three months from the date of purchase, where related queries will be answered within 24 business hours over telephone or email.
Related Products
